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The mechanisms underlying prion-linked neurodegeneration remain to be elucidated, despite several recent advances
in this field. Herein, we show that soluble, low molecular weight oligomers of the full-length prion protein (PrP), which
possess characteristics of PrP to PrPsc conversion intermediates such as partial protease resistance, are neurotoxic in
vitro on primary cultures of neurons and in vivo after subcortical stereotaxic injection. Monomeric PrP was not toxic.
Insoluble, fibrillar forms of PrP exhibited no toxicity in vitro and were less toxic than their oligomeric counterparts in
vivo. The toxicity was independent of PrP expression in the neurons both in vitro and in vivo for the PrP oligomers and
in vivo for the PrP fibrils. Rescue experiments with antibodies showed that the exposure of the hydrophobic stretch of
PrP at the oligomeric surface was necessary for toxicity. This study identifies toxic PrP species in vivo. It shows that
PrP-induced neurodegeneration shares common mechanisms with other brain amyloidoses like Alzheimer disease and
opens new avenues for neuroprotective intervention strategies of prion diseases targeting PrP oligomers.
Citation: Simoneau S, Rezaei H, Sale `s N, Kaiser-Schulz G, Lefebvre-Roque M, et al. (2007) In vitro and in vivo neurotoxicity of prion protein oligomers. PLoS Pathog 3(8): e125.
doi:10.1371/journal.ppat.0030125
Introduction
Transmissible spongiform encephalopathies are infectious
neurodegenerative diseases. They are characterized by the
accumulation in the brain, and sometimes the lymphoid
tissues [1,2], of an abnormally structured form (PrPsc) of the
host prion protein (PrP) [3]. PrPsc may constitute the
infectious agent, also called prion, entirely [4] or in part
[5,6]. The mechanism of neurodegeneration that ultimately
leads to neuronal death and the occurrence of clinical
symptoms, however, is still not known [7,8]. It has become
apparent that immunohistochemically detectable PrPsc ag-
gregates, of various sizes ranging from ﬁne granular
deposition to amyloid plaques, do not represent the neuro-
toxic entity of prion diseases. Indeed, PrPsc is not detectable
in some cases of fatal familial insomnia [9], in lethal scrapie-
like disease in mice overexpressing mutant PrP transgenes
[10], in wild-type mice inoculated with bovine spongiform
encephalopathy [11,12] or fatal familial insomnia [13], and in
prion-infected mice with a P101L mutation in their PrP gene
[14]. The hypothesis has been made earlier that the critical
events in pathogenesis occur at the submicroscopic level [15].
On the other hand, PrP peptides comprising the hydro-
phobic domain (residues 106–126) of PrP are toxic to
cultured neurons [16–19]. N-terminally truncated PrP also
triggers neuronal death in the absence of expression of the
normal form of the protein [20]. This shows that PrP has
intrinsic properties that could render the protein toxic under
certain conditions.
There is growing evidence that in other brain amyloidoses,
preﬁbrillar soluble protein aggregates, rather than insoluble
ﬁbrils, are toxic [21–24]. In vivo, 56-kD dodecameric
assemblies of Aß1–42, dubbed Aß* (of note, PrP* has also
been proposed as the biologically reactive form of PrP [25]),
have been shown to be associated with memory deﬁcits in a
murine model of Alzheimer disease and to cause transient
memory impairment after injection in the brains of rats [26].
In a zebraﬁsh model, expression of polyQ-expanded frag-
ments of huntingtin lead to their accumulation as large SDS-
insoluble cell inclusions; however, apoptotic cells are devoid
of visible aggregates. Remarkably, the treatment with two
anti-prion compounds prevented the formation of insoluble
aggregates but did not suppress abnormal embryo morphol-
ogy or cell death, strongly suggesting that upstream soluble
huntingtin assemblies constitute the toxic culprit [27].
Recently, soluble oligomers presenting an enriched ß-
sheeted structure were proposed as intermediates in the
amyloidogenesis process featured in prion diseases [28–31].
PrP oligomers were toxic in vitro [32,33].
We wanted to further investigate the hypothesis that prion
diseases share a common mechanism of neurodegeneration
with other brain amyloidosis, and set out to study the toxicity
of PrP oligomers in vitro and in vivo in the presence or
absence of endogenous PrP expression. We found that PrP
oligomers exhibit considerably higher toxicity than PrP ﬁbrils
both in vitro and in vivo. PrP monomers were nontoxic. The
toxicity occurred whether or not the neurons expressed PrPc.
The toxicity of PrP oligomers could be abrogated by blocking
the hydrophobic domain at the surface of the oligomers. We
propose a comprehensive model of the possible mechanisms
of prion-induced neurodegeneration.
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Production and Characterization of PrP Oligomers
Two types of PrP oligomers were produced by either
thermal refolding or expression of PrP in form of a tandem
repeat.
A recombinant ovine PrP (23–234) was generated and
converted into a ß-sheeted form (ß-PrP) (Figure 1A and 1B,
left panel) by thermal refolding (see Materials and Methods
and [34]). Both the ß-sheeted and the a-helical conformers
had mobilities corresponding to a molecular weight of about
25 kDa by SDS-PAGE (Figure 1C, left panel).
Another type of PrP oligomer was created by exploiting the
ﬁnding that dimerization has been described as a primary
event in the PrP conversion and aggregation process [35].
Two monomeric PrP units were covalently linked head to tail
via a ﬂexible linker (Figure 1A, right panel). This protein
displayed a molecular weight double that of the monomeric
PrP in the presence of detergents (Figure 1C, right panel).
The tandem murine PrP presents a higher ß-sheeted content
than the monomeric PrP as judged by the increase in the
1,618 cm
 1-peak (Figure 1B, right panel). Size exclusion
chromatography of both types of PrP preparations in
physiological buffers showed that they were exclusively in
an oligomeric state ([36] and Figure 1D). In summary, the
tandem mouse PrP oligomerized spontaneously after puriﬁ-
cation, while the ovine PrP oligomerized after heating. These
results are consistent with the recent ﬁnding that a-PrP
molecules convert into ß-sheeted oligomers with a molten
globule intermediate in the absence of any detectable ß-
sheeted monomeric PrP intermediate [37]. Both types of PrP
oligomers showed slightly enhanced thioﬂavine T binding
(Figure 1E), strongly suggesting that they were on the pathway
of amyloid ﬁbril formation (see below).
Oligomeric PrP Is Slightly Proteinase K Resistant
We investigated whether oligomeric PrP was more resistant
to proteinase K (PK) digestion than monomeric PrP. Each
type of PrP was submitted to a range of PK concentrations.
Both murine and ovine PrP oligomers exhibited partial
resistance to PK digestion when compared to their respective
monomeric counterparts (Figure 1C), as shown by i) the
difference in the degradation proﬁle between the tandem PrP
oligomers and the monomer at 500 ng/ml and 1 lg/ml (the
degradation of the tandem levels out, whereas the monomer
continues to be degraded (compare arrows #1); ii) a PK-
resistant core of the tandem of 36 kDa, which appears with
increasing PK concentrations (see arrow #2); iii) the 20-kDa
degradation product from the tandem increases with
increasing concentrations of PK contrarily to the same 20-
kDa product from the monomer (compare arrows #3); and iv)
the residual ;25-kDa band of the ovine ß-PrP observed at the
PK concentration of 500 ng/ml (albeit weak, this signal was
reproducible between experiments), contrasting with the
complete digestion of ovine PrP monomers at the same
concentration (arrows #4).
Oligomeric PrP Is Neurotoxic to Mouse Cortical Neurons
We ﬁrst analyzed the neurotoxic properties of the PrP
oligomers in a murine primary cortical neuron model.
Exposure of the neurons to both types of PrP oligomers
resulted in a loss of nearly 50% of the neurons when
compared to the untreated control cells, at a dose of 200 lg/
ml (Figure 2A) and 100 lg/ml (Figure 2D), both corresponding
to a concentration of 3 lM. Hence, oligomeric PrP exhibited
a roughly 30-fold higher toxic effect than the PrP peptide
105–132, which inserts into cellular membranes, and which
induced 40% neuronal death at 100 lM (Figure 2E). The same
levels of toxicity were observed in PrP
0/0 neurons, indicating
that the effect was not dependent on the expression of PrP by
the cells (Figure 2B for murine PrP oligomers, data not shown
for ovine PrP oligomers). We then wanted to verify that the
seven–amino acid linker or the His expression tag present in
the murine PrP oligomers were not responsible for their
toxicity. Neither the linker, ﬂanked on both sides by ten
residues from the N- and C-terminal regions of the PrP
sequence, (Figure 2C) nor grb-2 [38], an irrelevant protein of
the same size as PrP (217 aa), generated in the same
expression system as the tandem PrP and carrying the same
His-tag, were toxic to the neurons (Figure 2A and data not
shown).
To understand the type of neuronal death induced by these
oligomers, the cells were analyzed morphologically using
nuclear staining. Neuronal cultures treated with murine or
ovine PrP oligomers (Figure 2F) revealed a high quantity of
cells exhibiting condensed and fragmented chromatin, a
hallmark of apoptosis.
The Hydrophobic Domain of PrP Oligomers Is Essential for
Toxicity
To identify the domains of PrP oligomers accountable for
the observed toxicity, we occluded different regions of PrP
oligomers by incubating them with a series of domain-speciﬁc
PrP antibodies. Neurons exposed to murine or ovine PrP
oligomers were fully protected against cell death using the
monoclonal antibody Pri303 directed against the domain
106–126 of PrP (Figure 3 and data not shown). In contrast,
incubation with the PrP monoclonal antibodies SAF84 (aa
161–170), Pri917 (aa 217–221), or SAF32 (aa 59–92) had no
protective effect. These data show that the exposure of
hydrophobic domain of PrP at the surface of the PrP
oligomers is required for the neurotoxic mechanism. The
effect of the various antibodies was similar on neurons
expressing PrP or not (Figure 3), conﬁrming in an independ-
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Author Summary
Prion diseases are transmissible neurodegenerative diseases caused
by an infectious agent thought to be composed mainly of a host
protein, the prion protein (PrP). The mechanisms of neurodegener-
ation prevailing in these diseases are not well understood. In the
present study, we demonstrate that small PrP aggregates, called
oligomers, cause the death of neurons in culture and after injection
in vivo. On the contrary, larger PrP aggregates, visualized as fibrils by
electron microscopy, do not cause the death of cultured neurons
and are much less toxic than PrP oligomers in vivo. We propose that
the PrP oligomers exert their toxicity by disturbing neuronal
membranes, as well as by an excessive intracellular concentration
leading to the generation of death signals (also called apoptotic
signals) by the cell. Moreover, the use of antibodies recognizing a
certain portion of the PrP oligomers could prevent neuronal death.
This study assigns prion diseases to the same group of diseases as
Alzheimer disease, in which protein oligomers constitute the major
trigger of the neurodegenerative process, and suggests new
possible neuroprotective approaches for therapeutic strategies.Figure 1. Characterization of PrP Species
(A) Molecular representation of the PrP proteins used. Left: ovine PrP. Right: covalently linked tandem PrP constructed by associating two mature
murine PrP sequences (aa 23–231, not containing N- and C-terminal signal peptides) with a 7–amino acid linker sequence in a head-to-tail manner. The
proteins were purified as described in the Materials and Methods section.
(B) Fourier transform infrared spectra (FTIR) of recombinant PrP proteins. Left: ovine a-PrP (blue) and ß-PrP (red). Right: monomeric (blue) and tandem
(red) mouse PrP proteins. The results confirm the ß-sheeted conformation of the ß-PrP and indicate that the tandem PrP adopts a ß-sheet-enriched
conformation in physiological buffers.
(C) PK sensitivity of PrP species. PrP proteins were subjected to a PK digestion of 15 min at various concentrations of PK ranging from 100 ng/ml to 10
lg/ml. Both ovine ß-PrP (left) and mouse tandem PrP (right) exhibited partial protease resistance. The results are representative of at least two
independent experiments. The numbered arrows point to locations where differences in PK resistance can be observed between monomeric and
oligomeric PrP.
D) Size exclusion chromatography performed on ovine PrP (black and blue lines) and covalently linked tandem PrP (red line) in PBS buffer, immediately
after purification. The black line corresponds to the a-helical ovine PrP monomers; the blue line corresponds to the refolded, ß-sheeted ovine PrP
preparations (very small monomeric peak, major bimodal oligomeric peak with an excess of 12 mers compared to the 36 mers); the red line corresponds
to the murine tandem PrP preparations (very small monomeric peak, large oligomeric peak around the 36-mer peak of the ovine PrP oligomers, and
sharp peak on the left corresponding to highly aggregated molecules that eluted in the column void volume,V0).
(E) Thioflavine assay, which measures the fluorescence intensity of thioflavine bound to amyloiditic protein. Orange, fibrils of ovine PrP; blue, ovine PrP
oligomers 15 lM; red, murine tandem PrP oligomers 15 lM; black, ovine monomers 15 lM.
doi:10.1371/journal.ppat.0030125.g001
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neurons regardless of the expression of PrPc, and showing
that the prevailing neurotoxic mechanism can not be
counteracted by endogenous PrPc present at the cell surface.
PrP Fibrils Are Not Toxic on Primary Cortical Neurons
We then wanted to determine whether toxicity was limited
to oligomeric PrP species or if PrP ﬁbrils could also be toxic.
We established that aging of PrP oligomers (a temperature-
Figure 2. Neurotoxicity of Oligomeric PrP
(A–C) E15 cortical neurons from PrP
þ/þ(A) or PrP
0/0 (B) were exposed to various concentrations of murine PrP oligomers (red bars) for 72 h, and then cell
viability was measured using MTT. Untreated neurons (black bars) and neurons treated with either equivalent volumes of vehicle solution (light blue
bars) or a peptide mimicking the linker region of the mouse tandem PrP (dark blue bars) were chosen as controls (see [C] for molecular details of the
peptide).
(D) Cell viability measurements of neurons treated with either ovine PrP oligomers (dark red bars) or ovine PrP monomers (light red bars). The black and
light blue bars correspond to untreated and treated with vehicle solution controls, respectively.
(E) To compare the toxicity of the PrP preparations with a known toxic PrP peptide, PrP
þ/þneurons were incubated with the PrP peptide 105–132 (dark
green bars) and its scrambled version (light green bars) at two concentrations reported to induce neuronal death [18]. The cell viability results are
expressed as a percentage relative to the untreated control (black bar)þSEM. The results are representative of at least two independent experiments
performed with triplicate samples. The significance of the results was evaluated using a two-tailed unpaired student t-test with Welch corrections when
needed (significant ¼ *, 0.01 , p   0.05; very significant ¼ **, p   0.01).
(F) Hoechst 33342 nuclear staining of embryonic cortical neurons incubated with toxic recombinant proteins. Left: No protein control, showing normal
fully rounded cell nuclei. Middle: incubated with mouse PrP oligomers. Right: incubated with ovine PrP oligomers. Condensed nuclei characteristic of
apoptotic cells are seen in treated cells (white arrows).
doi:10.1371/journal.ppat.0030125.g002
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month at 4 8C) led to their polymerization into PrP ﬁbrils.
Figure 4A shows by electron microscopy that PrP oligomers
exhibit a mixed granular and protoﬁbrillar structure, while
aged preparations form long mature ﬁbrils 15 nm in
diameter. These ﬁbrils had amyloid properties as they
strongly bound to thioﬂavine T (Figure 1E); they also showed
enhanced PK resistance when compared to the PrP oligomers
(not shown). Toxic PrP oligomers were soluble in sodium
acetate, whereas aged PrP proteins were insoluble (Figure 4C,
compare young and aged in the pellet fraction-P-). Fibrillar
PrP preparations were not toxic, in contrast with oligomeric
PrP (Figure 4B).
PrP Oligomers Exhibit Higher Neurotoxicity than PrP
Fibrils In Vivo, and the Toxicity Is Independent of
Endogenous PrP Expression
To investigate the toxicity of different forms of PrP in vivo,
stereotaxic subcortical injections of oligomeric or ﬁbrillar
PrP were carried out in the right hemispheres (ipsilateral) of
C57BL/6 PrP
þ/þ or C57BL/6 PrP
0/0 mice, and monomeric PrP
or buffer alone was injected in the left hemispheres
(contralateral). Table 1 and Figure 5 describe the experiments
performed with ovine PrP preparations. The injection
scheme is summarized in Table 1. Figure 5A shows the
precise site of injection, just above the CA2 region of the
hippocampus. The effect of the PrP preparations on neuronal
toxicity was examined 24 h post-injection. The whole brains
were sectioned and carefully screened for toxicity by
gallocyanine staining, even though toxicity was detected only
at the expected site in the CA2 region of the hippocampus.
No toxicity was observed in mouse brains injected with buffer
alone or PrP monomers (Figure 5C, 5E, 5G, and 5I). PrP
oligomers were highly toxic in both PrP-expressing and non-
expressing mice, leading to an almost complete destruction of
the pyramidal layer of neurons in the hippocampal region
underneath the injection site (Figure 5D and 5H). Murine PrP
oligomers were as toxic as ovine PrP oligomers (not shown).
In vivo, PrP ﬁbrils were also toxic but to a markedly milder
extent than PrP oligomers (Figure 5B and 5F). To see if the
neurons were dying by apoptosis, the cells were labeled with
ApopTag BrdU that binds to DNA breaks, a hallmark of
apoptosis. As seen in Figure 6J and 6K, hippocampal neurons
exposed to the toxic PrP oligomers exhibited intense BrdU
labeling, which indicates that the neurons underwent
apoptosis. Furthermore, the levels of BrdU labeling also
provided a direct comparison of the level of toxicity of PrP
oligomers versus PrP ﬁbrils, showing again that the oligomers
were more toxic than the ﬁbrils.
In summary, these data show in vivo that soluble particles
of PrP oligomers exert a high intrinsic neurotoxicity, whereas
large PrP ﬁbrils exhibit low neurotoxicity, both independ-
ently of endogenous PrPc expression.
Discussion
There is a growing belief that intermediates in the
formation of the protease-resistant prion protein PrPsc
(sometimes referred to as PrP* [25]), rather than PrPsc itself,
are the pathogenic forms of PrP [10,11,13,14]. Moreover,
there is evidence from other brain amyloidoses that soluble
oligomeric forms of the disease-associated protein constitute
the neurodegenerative trigger [21–24].
We tested this hypothesis using oligomeric ß-sheeted PrP
preparations. Throughout the study, we used two different
types of PrP preparations in order to obviate a possible bias
due to the method of oligomer preparation. One was a
murine tandem PrP construct that spontaneously formed
oligomers, while the other was an ovine PrP, the oligomerisa-
tion of which was induced by thermal refolding into ß-
sheeted PrP. Both have been characterized and used in
previous studies [36,39]. We observed remarkably similar
results with both types of oligomers in all the different
experiments performed throughout this study. These
oligomers were soluble in physiological buffers, showed mild
PK resistance, and aggregated into insoluble amyloid ﬁbrils
upon aging, therefore resembling presumed PrPc to PrPsc
conversion intermediates. We ﬁrst showed that ß-PrP
oligomers, but not a-PrP monomers, are toxic to cortical
neurons in culture, in accordance with previous studies
[32,33]. They were approximately 30 times more toxic than
PrP peptides (Figure 2E and [18]). We did not observe a
species-speciﬁc effect of murine versus ovine oligomers,
suggesting that the main toxicity mechanism does not depend
on a homologous interaction between PrPc and the PrP
oligomers. In fact, the toxicity was completely independent of
endogenous PrP expression by the neurons (Figure 2). The
toxic effect of the ß-PrP oligomers in PrP
þ/þ and PrP
0/0
neurons could be reversed by blocking the 106–126 hydro-
phobic stretch of PrP with the Pri303 antibody, suggesting a
direct role of this region in the toxicity. We have previously
Figure 3. Rescuing of Oligomeric PrP-Induced Toxicity by Domain-
Specific PrP Antibodies
Embryonic cortical neurons from PrP
þ/þ (left, light gray bars) or PrP
0/0
(right, white bars) were incubated with 200 lg/ml (3 lM) of mouse PrP
oligomers, in the presence or absence of PrP-specific monoclonal
antibodies directed against different regions of the PrP protein (SAF32:
59–92; Pri303: 106–126; SAF84: 161–170; Pri917: 217–221). The results are
expressed in terms of percentage relative to the untreated control (black
bar). The graphs are representative of at least two independent
experiments performed with triplicate samples. The significance of the
results was evaluated using a two-tailed unpaired student t-test with
Welch corrections when needed. * indicates significance of values in
relation to the untreated control (significant ¼ *, 0.01 , p   0.05; very
significant¼**, p   0.01).þindicates significance of values in relation to
the toxic dose (significant¼, 0.01 , p   0.05; very significant¼þ þ, p  
0.01).
doi:10.1371/journal.ppat.0030125.g003
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at the surface of our ß-PrP oligomers by 1-anilino 8-
naphthalene sulfonic acid (ANS) ﬂuorescence probing [36].
It is a phenomenon common to protein misfolding [40], and
other authors have shown that the hydrophobic stretch 90–
120 of PrP is available for antibody binding in ß-oligomers
[28]. Moreover, we have data (not shown) suggesting that ß-
PrP oligomers undergo an increased cellular uptake. One
possible explanation is that the hydrophobic surface of the
PrP oligomers favors their insertion into the lipid bilayer.
This ﬁnding is in accordance with studies using PrP peptides
encompassing the hydrophobic PrP domain, showing that
they insert metastably into membranes and are toxic
independently of PrPc expression [18,19]. Interestingly, the
SAF84 antibody actually increased the toxicity of the PrP
oligomers. This effect is not linked to its binding to cell
surface PrPc, since it was observed in PrP-expressing and
non-expressing cells. Because SAF84 binds to the S2-H2 hinge
loop involved in the oligomerization process [41], a possible
hypothesis is that it facilitates PrP oligomerisation and hence
increases the toxicity.
Upon aging, toxic ß-PrP oligomers assembled into insolu-
ble ﬁbrils that were not toxic on our primary cultures of
cortical neurons. This ﬁnding is in accordance with the fact
that the soluble, non-ﬁbrillar amidated version of the
hydrophobic PrP 106–126 peptide is toxic [42] and with the
emerging view that the pathogenesis of amyloidotic diseases
Figure 4. Relationship between PrP Ultrastructure, Solubility, and Neurotoxicity
(A) Electron microscopy analyses showing that PrP oligomers form granular aggregates and protofibrils (panel 2, scale bar¼100 nm). Upon aging, they
assemble into long robust fibrils of PrP (panel 3, scale bar¼50 nm). Ovine PrP oligomers are shown in the pictures (panels 2 and 3), but similar results
were obtained with murine tandem PrP oligomers.
(B) WST-1 cell viability measurements of cortical neurons treated with young (oligomeric) or aged (fibrillar) PrP showing that protofibrillar/oligomeric
PrP is highly toxic, whereas fibrillar PrP is not toxic. The significance of the values was evaluated using a two-tailed unpaired student t-test with Welch
corrections when needed. * indicates significance of values in relation to the untreated control (very significant¼**, p   0.01).þindicates significance
of values when compared with the toxic dose (very significant ¼þ þ , p   0.01).
(C) Solubility properties of PrP oligomers (young) and PrP fibrils (aged) in sodium acetate. Aged PrP forms insoluble aggregates as seen from the pellet
fraction (P¼pellet, S¼supernatant). A total protein control shows that equal amounts of each protein were used (right panel). Murine PrP oligomers
are shown in (B and C).
doi:10.1371/journal.ppat.0030125.g004
Table 1. Experimental Set-Up of In Vivo Toxicity Assays
Mouse
Number Genotype
Left Hemisphere
(Controls)
Right
Hemisphere
1P r P
þþ Buffer PrP fibrils
2P r P
þþ Monomeric PrP PrP fibrils
3P r P
þþ Monomeric PrP PrP fibrils
4P r P
00 Buffer PrP fibrils
5P r P
00 Monomeric PrP PrP fibrils
6P r P
00 Monomeric PrP PrP fibrils
7P r P
þþ Buffer Buffer
8P r P
00 Buffer PrP oligomers
9P r P
00 Monomeric PrP PrP oligomers
10 PrP
00 Monomeric PrP PrP oligomers
11 PrP
þþ Buffer PrP oligomers
12 PrP
þþ Monomeric PrP PrP oligomers
13 PrP
þþ Monomeric PrP PrP oligomers
doi:10.1371/journal.ppat.0030125.t001
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Prion NeurotoxicityFigure 5. In Vivo Neurotoxicity of Ovine PrP Oligomers and Fibrils
(A) Schematic representation of a coronal section of a mouse brain with arrows indicating the injection sites of the PrP preparations.
(B–I) Nissl-like staining (gallocyanine) of the hippocampal region CA2-CA3 from the brains of mice injected with the PrP preparations or control buffer.
Top panels represent the low magnification image (scale bar ¼ 100 lm) and bottom panels the high magnification image (scale bar ¼ 20 lm) of the
lesioned regions (and anatomically corresponding region for the buffer and nontoxic PrP monomers). (B–E) Wild-type C57BL/6 mice, (F–I) PrP0/0 C57BL/
6 mice.
(J and K) Higher toxicity of PrP oligomers versus PrP fibrils (wild-type C57BL/6 mice shown). Apoptotic pyramidal neurons in the lesioned hippocampal
region have been labeled with the ApopTag BrdU kit and appear in green (scale bar ¼ 50 lm).
doi:10.1371/journal.ppat.0030125.g005
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Prion Neurotoxicityis related to soluble oligomeric species rather than to high
molecular weight protein assemblies [21,24]. We then wanted
to verify in vivo the relevance of our in vitro ﬁndings. We
performed stereotaxical injections of either the control
solution, PrP monomers, PrP oligomers, or PrP ﬁbrils in the
supra-hippocampal region of C57BL/6 PrP
þ/þ or C57BL/6
PrP
0/0 mice (Figure 5). First, we conﬁrmed that ß-PrP
oligomers are highly toxic in vivo, both in PrP expressing
or non-expressing mice. Like the in vitro experiments, the
vehicle solution and a-PrP monomers were not toxic to the
neurons in vivo. As a comparison, 10 lg of the 118–135 PrP
peptide was toxic in vivo to retinal neurons after intravitreal
inoculation [43]. Second, we found that PrP ﬁbrils were toxic
in vivo, but clearly less toxic than ß-PrP oligomers. The same
phenomenon was observed in PrP
þ/þ and PrP
0/0 mice. This is
clearly shown in Figure 5 by the differences in the extent of
neuronal damage in the hippocampal cell layer and by the
difference in BrdU labeling for apoptosis. The fact that PrP
ﬁbrils revealed some toxicity in vivo but not in vitro may be
due to a different level of sensitivity of the neuronal
subpopulation examined in either case (hipocampal versus
cortical neurons), as well as an ampliﬁcation of toxicity in
vivo due to the presence of glial cells in the brain. Another
explanation may be that, in vivo, the ﬁbrils were partially
broken down into smaller, more toxic aggregates.
Another study showed in vitro that the toxicity of PrP
oligomers and ﬁbrils was dependent on the expression of PrP
[33], suggesting the existence of alternative pathways of
toxicity. Interestingly, the PrPc dependency of the PrP-
induced toxicity has always been a matter of debate [17,44–
46]. However, because these authors also observed a different
toxicity behavior of their PrP ﬁbrils in vitro than we did, we
reason that all these differences may be due to the ﬁbrils
corresponding to different variants of supramolecular PrP
assemblies. These variants would expose differently their
reactive interface and thus react differently with the cell
surface. Different shapes of PrP ﬁbrils might be related with
the ‘‘prion strain’’ phenomenon, causing the brain to
degenerate more or less rapidly and triggering the death of
different subset of neurons. Hence, apparent differences
between our in vitro study and that by Novitskaya et al.
teaches us that we may be revealing only different compo-
nents of the very complex phenomenon of neurodegenera-
tion induced by amyloidotic proteins. Therefore, while the
dissection of mechanisms in vitro is obviously important, in
Figure 6. Model for the Mechanism of Oligomeric PrP-Induced Neurodegeneration
The scheme is derived from previous findings by other authors and has been complemented with mechanisms suggested by our data. (1) PrP interacts
with its ligand LPrP on the cell surface to generate a signal necessary for cell survival. PrP binds to its natural ligand LPrP via its globular domain, while
the interaction of the flexible N-terminus of PrP with LPrP triggers signal transduction. (2) In a PrP knock-out cell, p can replace PrP for both binding and
signal transduction [20,64]. (3) In experimental models where truncated forms of PrP (DPrP) or Doppel (Dpl, a member of the PrP supergene family
harboring partial sequence and structure similarity with PrP) are expressed on a PrP
0/0 background, binding of DPrP or Dpl to LPrP occurs, but not signal
transduction in the absence of a complete N-terminus [20,56,57,65]. Suppression of PrP or p signaling triggers cell death. (4) PrP oligomers present an
altered interaction with LPrP. They bind, but do not trigger signal transduction, and thus by competition prevent PrPc (PrP
þ/þ cells) or p (PrP
0/0 cells)
binding to LPrP, resulting in cell lethality. (5) The hydrophobic domain of PrP at the surface of the oligomers enhances their insertion in the cellular
membrane. This leads to membrane dysfunction, and hypothetically to the formation of pore-like structures [19,54] inducing toxic signals. (6) At high
intracellular concentration, PrP oligomers accumulate in the aggresome [61] and saturate the proteasomal or other degradation pathways of the cell,
leading to the generation of apoptotic signals. (7) The hydrophobic domain of PrP oligomers interact abnormally with mitochondrial membranes,
leading to the release of cytochrome C (Cyt C) triggering the apoptotic cascade [66].
doi:10.1371/journal.ppat.0030125.g006
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effect on the brain.
In vivo, endogenous PrP is required to generate PrP
oligomers, but, as shown by our experiment where we have
externally provided the toxic PrP species to PrP
0/0 cells, not to
induce neuronal death. This is also in accordance with
ﬁndings in a transgenic mouse model where prion replication
and death of PrP
0/0 neurons occurred by exclusive astrocytic
prion release [46]. In another study, conditional suppression
of PrPc expression in neurons during murine prion infection
led to a halt in the neurodegenerative process and behavioral
alterations [47,48]. In this model however, even if PrPsc
continued to accumulate, it was found restricted to astro-
cytes, and the absence of supply of toxic PrP species in the
vicinity of neurons was probably key to the neuroprotective
effect.
Our in vivo ﬁndings are in accordance with the emerging
consensus that during prion diseases, small undetectable PrP
aggregates, rather than plaque-type PrP deposits, are respon-
sible for neuronal dysfunction and death. This is supported
by the lack of correlation between neuronal death and the
observation of PrP plaques in vivo [9,49,50]. Moreover, highly
aggregated extracellular deposits of PrP in scrapie-infected
‘‘anchorless’’ transgenic mice exhibit very low toxicity, if any
at all [51]. Even if not toxic, this amyloid PrP or another yet
unknown component is infectious, as evidenced by trans-
mission to wild-type mice. Interestingly, another recent study
suggests dissociation also beteween the presence of Prp
amyloid and prion infectivity [52]. In a previous study where
focal PrPsc aggregates where found in PrP
0/0 mice grafted
with PrP
þ/þ tissue, no toxicity was observed, possibly due to
the aggregation state of the PrPsc detected by immunohis-
tochemistry [45].
The ﬁnding that soluble PrP oligomers, preceding the
formation of PrP ﬁbrils, are the main neurotoxic species in
vivo, assigns prion diseases to the group of other brain
amyloidoses, like Alzheimer and Parkinson disease, with
regard to their mechanism of neurodegeneration [7]. The
commonality of this mechanism is remarkable. It involves a
conformational change of the protein monomer, leading to
the formation of soluble aggregates, which become insoluble
as the protoﬁlaments grow into amyloid ﬁbrils. An antibody
recognizing common structural elements from different
cytotoxic oligomers was able to inhibit their cellular toxicity,
hinting at a commonality also in the primary targets of
toxicity [22]. Because some amyloid proteins, like Aß, are
located in the extracellular space, whereas others (a-synu-
clein) are cytosolic, it is likely that cell membranes that are
accessible from both compartments constitute one of these
targets. The early preﬁbrilar aggregates of HypF-N (a disease-
unrelated protein used as a model to study aggregate-
forming, pathogenic proteins) were shown to be able to
permeate synthetic phospholipid membranes [53]. Recently,
the physical mechanism of toxicity associated with the
intermediate-size Aß peptide oligomers was found to be the
formation of conducting pores in lipid bilayers [54].
Figure 6 reviews the most probable scenarios of PrP-
induced toxicity, showing how our data feed into the context
of earlier ﬁndings. In this model, the toxicity of the PrP
oligomers would be 3-fold : the ﬁrst scenario is linked to the
conformational change of oligomeric PrP, resulting in the
loss of the N-terminal ﬂexibility in the oligomers, which
thereby mimic the effect of DPrP constructs described in
earlier studies (Figure 6, #3 and #4); the second is the
membrane insertion and destabilization of PrP oligomers,
similar to the effects of PrP peptides (Figure 6, #5); and the
third relates to the intracellular effects of PrP oligomers,
comparable to those described with cytoplasmic PrP (mainly
Figure 6, # 6).
In normal cells, PrPc is thought to convey a survival
message by interacting with a cell surface ligand, LPrP.
Several studies have shown that the PrPc binding domain is
located in the structured core of the protein while the
activating domain is in the ﬂexible N-terminus of the protein
[20,55–57] (Figure 6, #1). One of the scenarios proposed is
that in PrP
0/0 mice, a hypothetical functional homologue of
PrP (p) binds to LPrP and transduces the signal (Figure 6, #2).
However, PrP
0/0 mice engineered to express an N-terminally
truncated PrP, or a PrP truncated in the most C-terminal part
of the ﬂexible domain (DPrP) or Doppel (a protein of the PrP
supergene family that lacks the N-terminus equivalent of
PrP), harbor a neurotoxic phenotype, because Doppel and
DPrP bind to LPrP with higher afﬁnity than p but lack the
domain responsible for the transduction of the survival
message (this is the so-called Shmerling or Doppel effect;
Figure 6, #3). In PrP oligomers, the N-terminus of PrP is
thought to be buried [36] and hence the oligomers would
behave similarly to Doppel or DPrP with regard to their
interaction with LPrP (Figure 6, #4). Cellular uptake of PrP
oligomers is likely to induce intracellular toxicity by the
accumulation of protein oligomers at the mitochondrial
membrane, resulting in the release of cytochrome C and
subsequent activation of the apoptotic cascade (Figure 6, #7),
as suggested for Parkinson and Alzheimer diseases [58].
Finally, it has been shown that a highly concentrated
intracellular abnormal PrP species is likely to end up
accumulating in the aggresome/proteasome system [59,60].
Increased uptake and intracellular accumulation of PrP
oligomers is likely to saturate intracellular degradation
pathways like the proteasome, thereby triggering the apop-
totic cascade (Figure 6, #6). The latter neurotoxic mechanism
would also explain why most amyloid diseases are associated
with old age, when there is likely to be an increased tendency
of proteasome dysfunction and for proteins to become
misfolded or damaged, in conjunction with the reduced
efﬁciency of the molecular chaperone and unfolded protein
responses [61,62].
The present study establishes ß-PrP oligomers as a major
neurotoxic species in vitro and in vivo, which likely
represents the culprit PrP* responsible for the development
of transmissible spongiform encephalopathy–linked neuro-
degeneration. Targeting ß-PrP oligomers, and their hydro-
phobic domain in particular, will allow researchers to devise
rational neuroprotective treatments for these highly debili-
tating diseases.
Materials and Methods
Protein preparations. The recombinant proteins used in this study
were a monomeric mouse PrP sequence (23–231), a mouse tandem
PrP composed of two monomeric sequences linked head to tail from
the carboxy terminal to the amino terminal by a linker (ﬂexible
sequence) to allow for proper folding of the dimer, an a-helical sheep
PrP, and a ß-sheeted version of the sheep PrP. The grb-2 protein and
the linker sequence ﬂanked at both sides by ten amino acids of the
PrP sequence were used as control proteins.
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sequences without N- and C-terminal signal peptides. This recombi-
nant protein was expressed and puriﬁed as previously described [41].
The proteins were stored at  20 8C in their elution buffer (8 M urea,
20 mM sodium phosphate, 500 mM sodium chloride, 500 mM
imidazole, [pH 6.3]) until needed (see below).
The ovine PrP full-length protein was puriﬁed as described
previously [64]. Brieﬂy, the gene encoding the full-length ARQ
variant (A136 R154 Q171) was cloned in pET 22bþ and expressed by
IPTG induction in the Escherichia coli BL21 DE3 strain. After lysis,
sonication, and solubilization of the inclusion bodies with urea,
puriﬁcation and renaturation of the prion protein were performed
on an Ni Sepharose column by heterogeneous phase renaturation,
taking advantage of the intrinsic afﬁnity of the full-length protein for
Ni.
For conversion, PrP (pH 7.2 in 20 mM MOPS) was heated at 72 8C
for 15 min and cooled to room temperature. Fourier transform
infrared spectra conﬁrmed that in these conditions, PrP forms
oligomeric ß-sheeted PrP. The characterization and mechanism of
formation of these ß-sheeted oligomers is published elsewhere [36].
Brieﬂy, they form discrete 12-mer and 36-mer species, are oblate-
shaped, have distinct secondary structure features, and display
exposures of hydrophobic clusters.
The synthetic peptides used in this study were mouse PrP 105–132:
KTNLKHVAGAAAAG-AVVGGLGGYMLGSA and mouse PrP
scrambled 105–132: NGAGKAGMVGLYGAHG-ATAKVSLVGALA.
They were prepared as described in [18].
Storage and dialysis of proteins. Mouse proteins were stored at 20
8C in their elution buffer (see above). The proteins were dialyzed just
before use against ultrapure water or 10 mM sodium acetate (pH 4.5),
and the concentration was obtained by the micro BCA protein assay.
The sodium acetate did not affect the pH of the culture medium or
the viability of the neurons at the dilutions used.
Sheep PrPs were produced just before use and kept at 4 8C for a
maximum of 30 d.
Primary mouse cortical cultures. PrP
þ/þ mice used in this study
were wild-type C57BL/6 mice. PrP
0/0 mice were obtained by back-
crossing PrP knockout mice, kindly provided by Charles Weissmann,
with C57BL/6 mice over nine generations, and are therefore named
C57BL/6 PrP
0/0 mice. Primary cortical cells were extracted from 15-d-
old mouse embryos. Cortices were dissected under a binocular
microscope in Ca
2þ/Mg
2þ-free PBS (Invitrogen, http://www.invitrogen.
com/) supplemented with glucose at a ﬁnal concentration of 3%.
Then, they were carefully freed of meninges and incubated in trypsin/
EDTA solution (Eurobio, http://www.eurobio.fr/) for 10 min at 37 8C.
The trypsin was removed and the leftover was inactivated with DMEM
(Dulbecco’s Modiﬁed Eagle’s Medium, Invitrogen) containing 4.5 g/l
glucose, Glutamax-I, and 1% FCS (fetal calf serum, Invitrogen). Cells
were then mechanically dissociated using a ﬂame-narrowed Pasteur
pipette in the same culture medium. The cell suspension was then
centrifuged and the pellet resuspended in DMEM supplemented with
B27 (Invitrogen) and 3% FCS. Cells were seeded on plates coated with
10 lg/ml of poly-D-lysine (Sigma, http://www.sigmaaldrich.com/)
initially in DMEM supplemented with B27 (2%), FCS (3%), and 100
U/ml penicillin/streptomycin. After 2 d, the culture medium was
replaced by serum-free DMEM containing N2 supplements (1%;
Invitrogen) and penicillin/streptomycin. Cultures were kept in a 37 8C
water-saturated incubator at 5% CO2.
In vivo neurotoxicity experiments. Female C57BL/6 PrP
þ/þ and
C57BL/6 PrP
0/0 mice (see paragraph above) were anesthetized with
isoﬂurane (1%–2.5%) and positioned on a stereotaxic frame. Once
the bregma was identiﬁed and holes drilled, 2 ll of 1 mg/ml of various
PrP preparations or the same volume of buffer were injected into the
hippocampus of the ipsi and controlateral hemispheres (1.5 mm
posterior,þ/ 2.00 mm lateral, and 1.75 mm ventral to bregma, Figure
5A) at a rate of 0.4 ll/min. The animals were killed by cervical
dislocation at 24 h post-injection. The brains were dissected out, ﬁxed
in 4% buffered paraformaldehyde, and parafﬁn embedded. For the
visualization of the neurons, 5-lm horizontal sections from the mid-
brain region were stained for nucleic acids with gallocyanine
according to standard protocols. To test for apoptosis, adjacent
sections of selected brain sections were analyzed with the ApopTag
BrdU kit according to the manufacturer’s instructions (Molecular
Probes, http://probes.invitrogen.com/). Slides were examined on an
epiﬂuorescence Zeiss microscope (http://www.zeiss.com/). All animal
experiments were performed in accordance with national and
European Union (EU) regulations.
Proteinase sensitivity of PrP species. Analysis of PK resistance was
performed by incubating 10 lg/ml of each protein for 15 min in the
presence of various concentrations of PK at 37 8C. The samples were
then precipitated with four volumes of methanol, resuspended in the
loading buffer, and analyzed by western blot with the monoclonal
antibodies 8G8 and Pri917 for the ovine and mouse PrP samples,
respectively.
In vitro neurotoxicity experiments. For toxicity monitoring, cells
were seeded at a density of 7310
4 cells per wells in a 96-well poly-D-
lysine–coated plate (in each plate, only the 60 wells in the center
contained cells and the outer wells were ﬁlled with PBS to prevent
any drying). After 5 d in culture, neurons were incubated with the
different recombinant PrP proteins for 72 h. In order to keep steady
culture medium concentrations, the proteins were diluted in 23
culture medium and the proper volume of water and vehicle solution
were added to get a ﬁnal concentration of 13. For controls, the cells
were left untreated or were exposed to an equivalent volume of
vehicle solution.
Cell survival assays. After exposure of the neurons to the proteins,
the viability was measured either with MTT or with WST-1. For MTT,
the medium was replaced with 500 lg/ml of 3,[4,5 dimethylthiazol-
2yl]-2,5 diphenyltetrazolium bromide (MTT; Sigma) dissolved in PBS.
After 2 h of incubation at 37 8C, the solution was removed and the
blue formazan was solubilized with an isopropanol/HCL 1N (92:8)
solution. Then, the optical density was measured at 540 nm with a
reference wavelength of 630 nm. For WST-1 (Roche, http://www.
roche.com/), 10 ll of the reagent was added directly to the culture
medium containing the cells and incubated for 1.5 h. Then, optical
density measures were taken at 450 nm against a reference
wavelength of 630 nm. In this case, a negative control, consisting of
DMEM without cells, was used and subtracted from all samples.
Visualization of apoptotic cells. This was performed by staining cell
nuclei with Hoechst 33342. Cells were seeded in poly-D-lysine-coated
8-well Labtek (Labtek II; Nalgene Nunc International, http://www.
nalgenunc.com/) culture dishes at a density of 1.6 3 10
5 cells/wells.
After treatment with the recombinant proteins, the cells were
mounted with Vectashield (Vector Laboratories, http://www.
vectorlabs.com/) supplemented with 5 lg/ml of Hoechst 33342
reagent (Molecular Probes). The slides were visualized using an
axiovert (Zeiss) ﬂuorescence microscope.
Rescue experiments. All monoclonal PrP antibodies used in this
study have been puriﬁed with Protein-A or Protein-G afﬁnity
columns and dialyzed against ultra-pure water. These steps were
carried out to remove growth factors and anti-microbial agents from
the antibody solutions. Antibodies were added directly to the culture
media containing the recombinant proteins of interest. Then these
were incubated with the cells for 72 h.
Electron microscopy of PrP samples. All protein samples were ﬁrst
added (0.2–1.5 mg/ml) to serum-free DMEM containing N2 supple-
ments (to be in the same conditions as the neurotoxicity experiments)
and incubated for 2 h at 37 8C. Following this step, a 10-ll aliquot of
protein preparation was applied to formar- and carbon-coated grids.
The excess ﬂuid was drained with ﬁlter paper and the sample was
stained for 1 min with 2% uranyl acetate. The grid was air-dried and
examined in a Philips EM CM120 at 80 kV at a magniﬁcation of 15–
75000.
Solubility assay of PrP samples. Young and aged PrP dimers were
centrifuged at 100,000g for 1 h and the supernatant was separated
from the pellet. The PrP was then visualized by western blot with the
antibody 4H11.
Thioﬂavine T ﬂuorescence measurements. Thioﬂavine T ﬂuores-
cence mesurements were performed at 20 8C on a Jasco 6200
spectroﬂuorimeter (http://www.jascoint.co.jp/) with a 1 mm 3 10 mm
optical path-length cuvette. The concentation of protein was adjusted
to 15 lM (equivalent monomer) for each species before incubation
with 15 lM thioﬂavine T. Excitation was performed at 432 nm.
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